ChromaDex (NASDAQ:CDXC – Get Free Report) released its earnings results on Thursday. The company reported $0.02 earnings per share for the quarter, Zacks reports. ChromaDex had a return on equity of 5.06% and a net margin of 1.62%. The business had revenue of $25.58 million for the quarter, compared to analyst estimates of $23.70 million. During the same quarter last year, the firm posted ($0.01) earnings per share. ChromaDex updated its FY 2024 guidance to EPS.
ChromaDex Trading Up 67.9 %
Shares of ChromaDex stock traded up $2.37 during trading hours on Friday, reaching $5.86. The stock had a trading volume of 37,543,352 shares, compared to its average volume of 264,220. The firm has a market capitalization of $444.95 million, a PE ratio of 586.59 and a beta of 1.88. The stock’s 50 day moving average is $3.53 and its 200 day moving average is $3.23. ChromaDex has a twelve month low of $1.32 and a twelve month high of $5.98.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reaffirmed a “buy” rating and set a $6.00 target price on shares of ChromaDex in a research report on Friday, August 9th.
Insider Buying and Selling
In other news, Director Kristin Patrick sold 23,000 shares of the business’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $3.57, for a total transaction of $82,110.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 9.64% of the company’s stock.
ChromaDex Company Profile
ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.
Further Reading
- Five stocks we like better than ChromaDex
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- From PACs to Portfolios: Billionaire Bets and Investor Reactions
- How to Invest in Biotech Stocks
- AppLovin Stock Quadruples: What’s Behind the Bullish Sentiment?
- Top Biotech Stocks: Exploring Innovation Opportunities
- Battle of the Retailers: Who Comes Out on Top?
Receive News & Ratings for ChromaDex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex and related companies with MarketBeat.com's FREE daily email newsletter.
